

### Osteoporosis Management in Women with a Fracture– Cheat Sheet

<b>Weight:</b> 1	<b>Current Star:</b> 2	<b>Current Standing:</b> 39%	<b>Next Threshold:</b> 41%
------------------	------------------------	------------------------------	----------------------------

<b>Star Measure Description</b>
This measure shows the percent of female plan members who broke a bone and got screening or treatment for osteoporosis within 6 months.

<b>Measure Source</b>
<ul style="list-style-type: none"> <li>Chart Review &amp; Claims</li> <li>7/1/-6/30</li> </ul>

<b>Requirement Specifications</b>
The percentage of woman MA enrollees 67 - 85 who suffered a fracture and who had either a bone mineral density (BMD) test or prescription for a drug to treat osteoporosis in the six months after the fracture.

<b>Best Practice/ Call to Action</b>
<ul style="list-style-type: none"> <li>Recommend/schedule DXA scan for those with recent qualifying fracture or prescribe qualifying osteoporosis treatment medications within 6 months of the fracture</li> <li>Medical Record alerts (for clinics that have capability) for patients that had a fracture</li> </ul>

<b>Supplemental Data</b>
<p>CPT II Codes:</p> <ul style="list-style-type: none"> <li><b>3096F:</b> DXA ordered</li> <li><b>3095F:</b> DXA results documented</li> <li><b>4005F:</b> Medications Prescribed</li> <li><b>3096F-1P or 3095F-1P or 4005F-1P:</b> Medical reasons for not ordering DXA or medication</li> <li><b>3096F-2P or 3095F-2P or 4005F-2P:</b> Patient denies</li> <li><b>3096F-3P or 3095F-3P or 4005F-3P:</b> System reasons for not ordering</li> <li><b>3096F-8P or 3095F-8P or 4005F-8P:</b> DXA or medication not prescribed for other reasons</li> </ul>

<b>Medications</b>
<ul style="list-style-type: none"> <li>Biphosphonates</li> <li>Calcitonin</li> <li>Denosumab</li> <li>Raloxifene</li> <li>Teriparatide</li> </ul>

<b>Star Ratings Performance &amp; Trends</b>					
Year	1-Star	2-Star	3-Star	4-Star	5-Star
2020	< 31%	≥ 31% to < 41%	≥ 41% to < 50%	≥ 50% to < 67%	≥ 67%
2019	<29%	≥29% to <45%	≥45% to <57%	≥57% to <78%	≥ 78%
2018	<24%	≥24% to <42%	≥42% to <52%	≥52% to <71%	≥ 71%